![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Gratzke, Christian; Maanen, Rob van; Chapple, Christopher; Abrams, Paul; Herschorn, Sender; Robinson, Dudley; Ridder, Arwin; Stoelzel, Matthias; Paireddy, Asha; Yoon, Sang Jin; Al-Shukri, Salman; Rechberger, Tomasz und Müller, Elizabeth R.
(2018):
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
In: European Urology, Bd. 74, Nr. 4: S. 501-509
White, William B.; Chapple, Christopher; Gratzke, Christian; Herschorn, Sender; Robinson, Dudley; Frankel, Jeffrey; Ridder, Arwin; Stoelzel, Matthias; Paireddy, Asha; Maanen, Robert van und Weber, Michael A.
(2018):
Cardiovascular Safety of the (3)-Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.
In: Journal of Clinical Pharmacology, Bd. 58, Nr. 8: S. 1084-1091
Gacci, Mauro; Andersson, Karl-Erik; Chapple, Christopher; Maggi, Mario; Mirone, Vincenzo; Oelke, Matthias; Porst, Hartmut; Roehrborn, Claus; Stief, Christian und Giuliano, Francois
(2016):
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
In: European Urology, Bd. 70, Nr. 1: S. 124-133